Tessera Defense and Homeland Security Inc. (HLSQ) is a NYSE American-listed physical security technology company that operates a unified platform connecting cameras, sensors, detection technologies, artificial intelligence and other security infrastructure. News related to Tessera often focuses on how the company develops and deploys integrated security solutions for homeland security, critical infrastructure, energy, digital infrastructure and enterprise environments.
Coverage of Tessera can include announcements about enhancements to its unified security platform, updates on deployments that connect detection, intelligence and response across complex sites, and developments involving its subsidiaries. Zorronet, which provides AI-powered security intelligence and autonomous command-and-control capabilities, and DFSL, which develops LADAR-based counter-UAS and perimeter security systems, may feature in reports about advanced sensing, real-time intelligence and autonomous response applications.
Another important theme in Tessera-related news is its corporate evolution. On September 11, 2026, the company changed its legal name from BiomX Inc. to Tessera Defense and Homeland Security Inc. and began trading under the HLSQ ticker, replacing PHGE. Articles and releases may reference this transition and explain that older items under the BiomX name or PHGE symbol document the issuer’s former biotechnology business rather than its current security focus.
Investors, analysts and security professionals following Tessera’s news can expect information about platform capabilities, customer segments such as critical infrastructure and homeland security organizations, and the company’s role in addressing evolving physical threats, including those involving unmanned and autonomous systems. Historical news under the BiomX identity remains part of the record but should be interpreted in light of the company’s subsequent shift to physical security technology.
BiomX (NYSE: PHGE) announced that its Zorronet subsidiary launched a secure, mobile command-and-control app now available on Google Play and the Apple App Store.
The app integrates cameras, sensors, drones, and IoT into a single AI-driven operational view, delivers role-based structured alerts, and is already used by cities, regional councils, and Israel Railways.
BiomX (NYSE:PHGE) said its Zorronet unit completed a year-long pilot with Israel Railways, achieving a 98% success rate keeping large animals off tracks after a pilot investment of ~NIS 800,000. Zorronet signed a 12-month framework to supply AI alert stations (initially 15 stations) with 120-meter detection range, maintenance, and 24/7 service, and expects additional station orders as it scales across Israel Railways’ ~1,700 km network. The release also notes Zorronet’s defense work and BiomX’s acquisition of DFSL LADAR technology.
BiomX (NYSE: PHGE) accelerated exercise of an exclusive option and entered a definitive agreement to acquire a controlling interest in DFSL, an Israeli defense engineering company that develops LADAR-based perimeter, critical infrastructure and counter-UAS detection systems.
The acquisition pairs DFSL’s ~99% accurate LADAR sensing with BiomX’s Zorronet AI command-and-control platform, aiming to create an integrated detection-to-response security solution. Consideration includes cash, an unsecured convertible note, warrants exercisable at $12, and a revenue-tied bonus; the deal is subject to Israeli regulatory and NYSE American shareholder approvals.
BiomX (NYSE:PHGE) completed the acquisition of 100% of Zorronet from Water.io on April 10, 2026, entering the defense, rescue and security sector.
Zorronet supplies AI command-and-control software integrating video analytics, drones, sensors and IoT, with contracts including the Israel Defense Forces and Israel Railways. BiomX says the move complements its option to acquire DFSL and targets a combined ~$81B command-and-control and video analytics market by 2030.
BiomX (NYSE American: PHGE) entered an option agreement to acquire control of DFSL, a developer of LADAR (laser radar) detection systems, with the transaction estimated at approximately $45 million if closed. Consideration may include cash, a convertible promissory note, common shares and warrants exercisable at $12 per share. BiomX plans to pivot into security, defense and first-response markets; the deal is subject to Israeli regulatory approval and customary closing and shareholder approvals. DFSL’s platform claims ~99% real-world detection accuracy and is deployed in transportation and defense settings.
BiomX (NYSE: PHGE) appointed Dr. Ehud (Udi) Levi to its newly formed Advisory Board on March 30, 2026. Dr. Levi will advise as the company evaluates expansion into security, defense, aerial response and counter-UAS technologies, focusing on partnerships, transactions and new business directions.
Dr. Levi brings more than three decades in Israeli intelligence, including service in Unit 8200, leadership of the Counter-Terror Finance Office, and tenure as Deputy to the Director of the Mossad. Compensation will align with the company’s existing incentive plan.
BiomX (NYSE American: PHGE) received a March 25, 2026 notice that it does not meet NYSE American stockholders' equity minimums in Sections 1003(a)(i)-(iii). The company must submit a compliance plan by April 24, 2026 to regain compliance by September 25, 2027.
The Notice does not affect current listing or trading and the company previously disclosed a going concern paragraph in its 2025 audited financial statements.
BiomX (NYSE: PHGE) launched X Security & Defense LTD. in Israel on March 26, 2026 and will finance 2026 operations with over $3 million from internal funds. The company signed a non‑binding LOI for exclusive Israel distribution of an advanced aerial firefighting drone system.
BiomX aims to commercialize security, defense and first‑response technologies amid growing UAV emergency markets (UAV emergency responders: $3.2B 2023 → $9.6B 2032; firefighting drones: $1.8B 2023 → $4.5B 2032) and cites Israeli government emergency budgets exceeding $500 million.
BiomX (NYSE American: PHGE) CEO Michael Oster outlined a strategic and financial reset on March 19, 2026, aimed at stabilizing finances, simplifying capital structure, and unlocking future growth.
Key action: warrants from a December 2025 investment were amended to a one-year exercise period with an $1.00 exercise price, per the Form 8-K. Management is cutting non-essential costs, closing a Maryland facility, engaging banks and investors, and exploring repositioning toward defense-related opportunities.
BiomX (NYSE American: PHGE) announced on March 9, 2026 the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer to support the company’s next growth phase. Both executives bring senior experience in M&A, corporate strategy, finance, and capital markets.
BiomX is a clinical-stage company developing natural and engineered phage therapies targeting harmful bacteria in chronic diseases; the new leaders will focus on execution, capital strategy, and investor engagement.